Prof Porta speaks to ecancer about the final follow up data for CheckMate -9ER.

This study compares treatment options for metastatic kidney cancer, focusing on sunitinib versus a combination of nivolumab and cabozantinib.

The trial shows significant improvements in progression-free and overall survival with the combination treatment.

Many patients achieve complete response, leading to longer survival rates.

Effective management of side effects is crucial, and the combination is now a standard treatment option for this condition.